Prior malignancy; except for adequately treated basal cell or squamous cell skin cancer or noninvasive carcinomas Patients with pre existing Grade II peripheral neuropathy Patients with prior chemotherapy Stage IV or metastatic breast cancer Pregnant or nursing women Inability to cooperate with treatment protocol No active serious infections or other conditions precluding chemotherapy Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol (e.g. unstable angina, myocardial infarction within 6 months, severe infection, etc.) Known hypersensitivity to any component of required drugs in the study Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C or active hepatitis Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities (Prior to study entry, any electrocardiograph [ECG] abnormality at screening has to be documented by the investigator as not medically relevant)